The Experts below are selected from a list of 81 Experts worldwide ranked by ideXlab platform
P Wolf - One of the best experts on this subject based on the ideXlab platform.
-
reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation interest of continuous glucose monitoring
2002Co-Authors: Laurence Kessler, Raphael Passemard, Lionel Badet, Pascal Alain Robert Bucher, Pierre Meyer, Christian Toso, Jose Oberholzer, Alfred Penfornis, Pierre Yves Benhamou, P WolfAbstract:OBJECTIVE —To compare the glycemic profiles of patients with type 1 diabetes treated with either an Implantable Insulin Pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS —The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal Insulin infusion through an Implantable Pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were Insulin independent, whereas three IAK patients had partial graft function and reduced exogenous Insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events ( RESULTS —The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 ± 1.12 and 5.83 ± 0.81 vs. 7.81 ± 1.55 mmol/l ( P P P P CONCLUSIONS —Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an Implantable Insulin Pump requires Insulin delivery by a closed loop.
Laurence Kessler - One of the best experts on this subject based on the ideXlab platform.
-
reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation interest of continuous glucose monitoring
2002Co-Authors: Laurence Kessler, Raphael Passemard, Lionel Badet, Pascal Alain Robert Bucher, Pierre Meyer, Christian Toso, Jose Oberholzer, Alfred Penfornis, Pierre Yves Benhamou, P WolfAbstract:OBJECTIVE —To compare the glycemic profiles of patients with type 1 diabetes treated with either an Implantable Insulin Pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS —The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal Insulin infusion through an Implantable Pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were Insulin independent, whereas three IAK patients had partial graft function and reduced exogenous Insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events ( RESULTS —The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 ± 1.12 and 5.83 ± 0.81 vs. 7.81 ± 1.55 mmol/l ( P P P P CONCLUSIONS —Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an Implantable Insulin Pump requires Insulin delivery by a closed loop.
Pierre Yves Benhamou - One of the best experts on this subject based on the ideXlab platform.
-
reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation interest of continuous glucose monitoring
2002Co-Authors: Laurence Kessler, Raphael Passemard, Lionel Badet, Pascal Alain Robert Bucher, Pierre Meyer, Christian Toso, Jose Oberholzer, Alfred Penfornis, Pierre Yves Benhamou, P WolfAbstract:OBJECTIVE —To compare the glycemic profiles of patients with type 1 diabetes treated with either an Implantable Insulin Pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS —The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal Insulin infusion through an Implantable Pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were Insulin independent, whereas three IAK patients had partial graft function and reduced exogenous Insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events ( RESULTS —The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 ± 1.12 and 5.83 ± 0.81 vs. 7.81 ± 1.55 mmol/l ( P P P P CONCLUSIONS —Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an Implantable Insulin Pump requires Insulin delivery by a closed loop.
Lionel Badet - One of the best experts on this subject based on the ideXlab platform.
-
reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation interest of continuous glucose monitoring
2002Co-Authors: Laurence Kessler, Raphael Passemard, Lionel Badet, Pascal Alain Robert Bucher, Pierre Meyer, Christian Toso, Jose Oberholzer, Alfred Penfornis, Pierre Yves Benhamou, P WolfAbstract:OBJECTIVE —To compare the glycemic profiles of patients with type 1 diabetes treated with either an Implantable Insulin Pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS —The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal Insulin infusion through an Implantable Pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were Insulin independent, whereas three IAK patients had partial graft function and reduced exogenous Insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events ( RESULTS —The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 ± 1.12 and 5.83 ± 0.81 vs. 7.81 ± 1.55 mmol/l ( P P P P CONCLUSIONS —Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an Implantable Insulin Pump requires Insulin delivery by a closed loop.
Raphael Passemard - One of the best experts on this subject based on the ideXlab platform.
-
reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation interest of continuous glucose monitoring
2002Co-Authors: Laurence Kessler, Raphael Passemard, Lionel Badet, Pascal Alain Robert Bucher, Pierre Meyer, Christian Toso, Jose Oberholzer, Alfred Penfornis, Pierre Yves Benhamou, P WolfAbstract:OBJECTIVE —To compare the glycemic profiles of patients with type 1 diabetes treated with either an Implantable Insulin Pump or pancreas or islet transplantation by the means of the continuous glucose monitoring system (CGMS; Minimed, Sylmar, CA). RESEARCH DESIGN AND METHODS —The CGMS enabled recording of subcutaneous glucose concentrations (range 2.2–22 mmol/l) over 72 h (288 measurements per day). Over 3 days, 26 patients with type 1 diabetes were connected to a CGMS: 10 patients were treated with intraperitoneal Insulin infusion through an Implantable Pump (IPII), 9 patients were treated with simultaneous pancreas-kidney transplantation (SPK), and 7 patients were treated with pancreatic islet transplantation after kidney grafting (IAK). All SPK patients and four IAK patients were Insulin independent, whereas three IAK patients had partial graft function and reduced exogenous Insulin needs. Glucose control was evaluated by the mean glucose concentration, glucose variability, and the number and duration of hypoglycemic events ( RESULTS —The mean glucose concentration and the glucose variability in SPK and IAK patients were significantly lower than those observed in patients treated with IPII: 5.38 ± 1.12 and 5.83 ± 0.81 vs. 7.81 ± 1.55 mmol/l ( P P P P CONCLUSIONS —Use of subcutaneous CGMS confirms that islet transplantation can be as efficient as pancreas transplantation in restoring good metabolic control and reducing blood glucose variability. Metabolic improvement due to use of an Implantable Insulin Pump requires Insulin delivery by a closed loop.
